Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers.
Koch, K., Kalusche, S., Torres, J.L., Stanfield, R.L., Danquah, W., Khazanehdari, K., von Briesen, H., Geertsma, E.R., Wilson, I.A., Wernery, U., Koch-Nolte, F., Ward, A.B., Dietrich, U.(2017) Sci Rep 7: 8390-8390
- PubMed: 28827559 
- DOI: 10.1038/s41598-017-08273-7
- Primary Citation of Related Structures:  
5U64, 5U65 - PubMed Abstract: 
Broadly neutralizing antibodies (bnAbs) against HIV-1 protect from infection and reduce viral load upon therapeutic applications. However no vaccine was able so far to induce bnAbs demanding their expensive biotechnological production. For clinical applications, nanobodies (VHH) derived from heavy chain only antibodies from Camelidae, may be better suited due to their small size, high solubility/stability and extensive homology to human VH3 genes ...